Investigators
Chris Blyth, Anita Williams
Partners
Australian Group on Antimicrobial Resistance (AGAR)
Project description
Bacteraemia is associated with significant morbidity and mortality in children and adults, more frequently affecting neonates, Indigenous children and children admitted to hospital. The Australian Group on Antimicrobial Resistance (AGAR) Surveillance Outcome Program captures clinical and microbiological data to monitor changes in antimicrobial resistance in bacteraemia isolates.
The aim of this analysis is to describe the microbiological and clinical characteristics of paediatric patients and investigate any differences between the paediatric and adult populations with bacteraemia in Australia whose data has been collected in the AGAR surveillance system
The objectives are
- Describe the microbiological and clinical characteristics of paediatric patients with bacteraemia whose data has been collected in the AGAR surveillance system
- Examine and describe trends in the microbiological data over time stratified by age and location, including detailed antibiotic susceptibility patterns of patients with a MDR organism infection, including (but not limited to) Methicillin-Resistant Staphylococcus aureus (MRSA), Expended-Spectrum Beta-Lactamase (ESBL) positive and Carbapenem Resistant Gram-negative infections
- Explore and compare the differences between the adult and paediatric populations for causative pathogens and resistance profiles within the AGAR surveillance system over time
External collaborators
Anita Campbell, Denise Daley, Jan Bell, Geoff Coombs, Alison Kesson, Phoebe Williams, Brendan McMullen, Adam Irwin, Morgyn Warner, Louise Cooley